RxDoctor Payments Data

Hiyas Fonte, MD

Internal Medicine · Southlake, TXNPI 1669405064

Payments from drug & device makers

$457in general payments, 2019–2025

Across 29 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$159
  • AbbVie$71
  • Boehringer Ingelheim$36
  • Medtronic$32
  • Dexcom, Inc.$31
  • Sanofi-aventis U.S. LLC$22
  • plus $106 from 7 others

What the payments were for

  • Food & beverage$44597%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK11$159
AbbVie(2 entities)5$71
Boehringer Ingelheim2$36
Medtronic1$32
Dexcom, Inc.2$31
Sanofi-aventis U.S. LLC1$22
Abbott1$20
Johnson & Johnson1$20
Novo Nordisk1$15
Ascend Therapeutics US, LLC1$15
Amgen1$12
Sanofi Pasteur Inc.1$12
Lilly USA, LLC1$12

How this compares

$457 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$128,041
Medicare patients
349
Services billed
2,514

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$78,744
JardianceEmpagliflozin38$55,656
RybelsusSemaglutide27$46,131
XareltoRivaroxaban28$40,479
MounjaroTirzepatide30$33,691
EliquisApixaban29$29,955
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,587
SynthroidLevothyroxine Sodium135$10,958
Advair HfaFluticasone Propion/Salmeterol17$5,023
Estradiol72$4,908
Atorvastatin Calcium365$3,485
SymbicortBudesonide/Formoterol Fumarate11$2,986
Levothyroxine Sodium279$2,861
Rosuvastatin Calcium239$2,639
Duloxetine Hcl77$2,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$15$124,87490 claims
Boehringer IngelheimJardiance$36$55,65638 claims
Johnson & JohnsonXarelto$20$40,47928 claims
Lilly USA, LLCMounjaro$12$33,69130 claims
GSKTrelegy Ellipta$159$16,58716 claims
AbbVieSynthroid$71$10,958135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Southlake

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →